Pricing Intelligence and Data for Innovators
If you are an innovator of any size looking to outsource development and/or manufacturing for fast-tracked COVID-19 therapeutics or vaccine programs, the Nice Insight 2020 Large Molecule Therapeutics & Vaccines Market Report & CDMO Pricing Study + COVID-19 Update is your resource for information. With in-depth profiles on 49 Biologics CDMOs that offer outsourced services, you can determine which companies are a match for your COVID-19 projects. The report also includes pricing data, so you can calibrate your cost expectations with competitive pricing comparisons.
What You Get With the Report
- Overview of COVID-19, SARS-CoV-2, and early therapeutic and vaccine development efforts.
- 2019 pricing benchmarks based on actual quotes given by providers for all typical service line items within biologic development projects.
- Ability to measure whether your pricing levels are right against high, low, and median pricing in the marketplace.
- A comprehensive view of the competitive landscape with a directory of 49 Biopharmaceutical CDMOs curated as relevant to COVID-19 programs across major regions, including capabilities, capacity, proprietary technologies, and facility locations.
- Input from subject matter experts (SMEs) from CDMOs and buyers of outsourced services.
- Segmented breakdown of the biologics development market by scientific process, therapeutic areas, regions, clinical and commercial production, etc.
- Analysis of advanced therapeutics in development, novel expression platforms, and advances in technology.
Gain More Understanding Of:
- High, low, and median pricing for all typical Biologics CDMO services
- Benchmark pricing and capacities among Biologics CDMOs
- Where capacity exists worldwide
- Awareness levels and perceptions of Biologics CDMO providers
- What matters to innovators seeking a CDMO for COVID programs
- How to select the best outsourcing partner on accelerated timelines
CDMO Pricing Study
Pricing benchmarks cover line items under:
- Methodology
- Discovery / Cell Line Development / IND
- Analytical Work
- Engineering / Manufacturing Run
- Additional Analytical Development
- Commercial Manufacturing
Large Molecule Therapeutics & Vaccines Market Report
- Executive Summary
- COVID-19: Background about the Virus and Early Therapeutic and Vaccine Development Efforts
- Understanding SARS-CoV-2
- Epidemiology of COVID-19
- Early Therapeutic and Vaccine Development for COVID-19
- Biopharma Market Overview
- Study Methodology
- Market Size
- Biopharma Market by Production Method
- Mammalian
- Microbial
- Other (plant, insect, etc.)
- Biopharma Market by Production Type:
Established Products
- Recombinant Proteins including Antibodies
- Plasmid Proteins
- Vaccines
- Biopharma Market by product Type:
Next-Generation Products
- Next-Generation Antibodies
- Viral Vectors
- Gene Therapies
- CAR-T Cell Therapies
- Stem Cell Therapies
- Biopharma Market by Development Stage
- Biopharma Contract Development and Manufacturing Market
- Services Offered
- Cell-line Engineering
- Development Activities
- Drug Substance Manufacturing
- Biopharmaceutical Analysis
- Fill/Finish
- Viral Fill/Finish
- Regional Analysis
- Recent Investments
- Biopharma Outsourced Manufacturing Pricing Study
- Methodology
- Discovery / Cell Line Development / IND
- Analytical Work
- Engineering/Manufacturing Run
- Additional Analytical Development
- Commercial
.svg)
